2261. Phosphaturia in HIV-exposed Uninfected Neonates Associated with Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy
Session: Poster Abstract Session: HIV: Metabolic, Cardiovascular, and Renal Complications
Saturday, October 6, 2018
Room: S Poster Hall
  • ID Week 2018 TDF-Neonate Poster.pdf (689.1 kB)
  • Background: Our recent study showed significantly lower bone mineral content (BMC) in HIV-exposed uninfected (HEU) neonates born to HIV-infected (HIV+) mothers who took tenofovir disoproxil fumarate (TDF) in late pregnancy compared to no TDF use. In this cohort we sought to understand possible mechanisms for lower BMC by comparing markers of bone metabolism and renal function with TDF exposure in HEU neonates.

    Methods: Among a subset of HEU children in the multicenter (US and Puerto Rico) observational Surveillance Monitoring for ART Toxicities (SMARTT) Cohort study, we enrolled neonates (≥ 36 wks gestational age) of HIV+ mothers who took TDF for ≥ 8 wks in the 3rd trimester (TDF+) or no TDF in pregnancy (TDF-). In addition to BMC measures, we collected a blood and urine sample on each child ≤ 30 days of birth to measure serum creatinine, phosphate, 25-OH vitamin D, parathyroid hormone and urine creatinine, phosphate and N-terminal telopeptide. Standard equations were used to estimate proximal tubular phosphate reabsorption and glomerular filtration rate (eGFR). Comparisons were made by TDF exposure using Wilcoxon and Fisher’s exact tests. We fit linear models to compare TDF+ and TDF- for each assay by age in days at sample collection (slope), stratified by age group at sample collection time (0-3 days, 4-30 days).

    Results: Of 160 HEU neonates (Black 71%, Hispanic 31%), 82 were TDF+ and 78 TDF-. Sociodemographic and anthropometric characteristics did not differ by TDF exposure in each age group. Within 0-3 days of life, TDF+ had a greater decline in serum creatinine (p=0.04) and a greater increase in eGFR compared to TDF- (p=0.06), but no difference in slope by TDF exposure within 4-30 days of life, nor in serum phosphate in either age group. Proximal tubular phosphate reabsorption was similar for both groups within the first 3 days of life, with a significantly greater decline in phosphate reabsorption between 4-30 days of life in the TDF+ compared to the TDF- group (p=0.006, Figure 1). Bone markers did not differ by TDF exposure for either age group. 

    Conclusion: Urinary phosphate loss was increased among HEU neonates of mothers who took TDF in late pregnancy. This suggests proximal tubular dysfunction and may explain, at least in part, the decrease in BMC previously described.

    Murli Purswani, MD, BronxCare Health System, Bronx, NY, Denise Jacobson, PhD, MPH, Tufts University School of Medicine, Nutrition Infection Unit, Boston, MA, Jeffrey Kopp, MD, NIDDK, NIH, Bethesda, MD, Russell Van Dyke, MD, Tulane University School of Medicine, New Orleans, LA, Linda DiMeglio, MD, Indiana University School of Medicine, Indianapolis, IN, Tzy-Jyun Yao, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Tracie Miller, MD, University of Miami Miller School of Medicine, Miami, FL, George Siberry, MD, MPH, FPIDS, NICHD, Bethesda, MD and For the Pediatric HIV/AIDS Cohort Study (PHACS)


    M. Purswani, None

    D. Jacobson, None

    J. Kopp, None

    R. Van Dyke, Giliad Sciences: Grant Investigator , Research grant .

    L. DiMeglio, None

    T. J. Yao, None

    T. Miller, None

    G. Siberry, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.